Fresenius SE & Co. KGaA I

Fresenius provides products and services for chronically ill patients through four segments: Medical Care, Kabi, Helios, and Vamed. Medical Care offers dialysis-related products and services. Kabi engages in therapy and care of critically and chronically ill patients, offering generic drugs, nutrition products, medical technologies, and more. Helios provides clinical and nursing care facilities. Vamed offers services for hospitals and healthcare facilities, including operational management and patient services. The company was founded in 1912 and is headquartered in Germany.

Overview

Sector

Medical Care Facilities

Target Price

38.3 EUR

Current Price

46.6 EUR

Potential

-18%

Strengths

Price to book ratio (1.33) is lower than the sector mean (3.45).
EV/EBIT (18.59) is lower than the sector mean.

Weaknesses

With a depreciation Potential of -17.02%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company has high debt. Net Debt to EBITDA Ratio (3.20) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (7.74%) is significantly lower than the sector mean (10.67%).

Key Financial Data

Indicator	Value
PER	55.7
EV/EBITDA	11.6
Price/Free Cash Flow'	17.2
ROIC	7.7%
Net Debt/EBITDA	3.2